- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
Research at a glance
Top areas of exploration
- Platelet Aggregation Inhibitors , 79 publications
- Percutaneous Coronary Intervention , 47 publications
- Purinergic P2Y Receptor Antagonists , 41 publications
- Clopidogrel , 35 publications
Research activity
Active clinical trials
- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
My publications
Filter publications
128 publications
2019
Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.
JACC. Basic to translational science
PubMed • Publisher's site2019
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Circulation
PubMed • Publisher's site2019
Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations.
Therapeutic advances in hematology
PubMed • Publisher's site2019
Switching Oral Anticoagulant Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions
PubMed • Publisher's site2019
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions
PubMed • Publisher's site